• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Atrial Fibrillation Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 Product Image

Atrial Fibrillation Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

  • ID: 2673551
  • October 2013
  • Region: Global
  • 88 Pages
  • Transparency Market Research

FEATURED COMPANIES

  • AtriCure, Inc
  • Biosense Webster, Inc
  • Boehringer Ingelheim GmbH
  • CardioFocus, Inc
  • Johnson and Johnson Ltd
  • Sanofi Aventis
  • MORE

'Atrial Fibrillation Market (Pharmacological and Non-Pharmacological Treatment, Electric Cardioversion, Radiofrequency, Cryo, Laser and Microwave Catheter Ablation, Maze Surgery, Anti-Coagulant and Anti-Arrhythmic Drugs) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019'

Atrial fibrillation is a type of cardiac arrhythmia identified by an abnormal cardiac rhythm caused by a disturbance in the heart’s electrical system. Atrial fibrillation (AF) is one of the most commonly occurring cardiac rhythm conditions. As a potentially life-threatening disease and a condition that's expensive to treat, the healthcare system views treatment for this condition as a strategically critical area to address. This report analyzes the market for atrial fibrillation from the point of view of various pharmacological and non-pharmacological treatment products.

The pharmacological AF treatment market has been further classified into the specific drugs commonly used for treating AF, namely anti-arrythmics and anti-coagulants. The non-pharmacological atrial fibrillation devices market has been further sub-divided into therapeutic procedures such as catheter READ MORE >

FEATURED COMPANIES

  • AtriCure, Inc
  • Biosense Webster, Inc
  • Boehringer Ingelheim GmbH
  • CardioFocus, Inc
  • Johnson and Johnson Ltd
  • Sanofi Aventis
  • MORE

Chapter 1 Preface
1.1 Report description
1.2 Market segmentation
1.3 Research methodology

Chapter 2 Executive Summary

Chapter 3 Market Overview
3.1 Introduction
3.2 Market Dynamics
3.2.1 Drivers
3.2.1.1 Rising global base of geriatric population
3.2.1.2 Favorable results exhibited by clinical trials aimed at treating atrial fibrillation
3.2.1.3 Rising prevalence of disorders such as hypertension and obesity accelerating the incidence rate of atrial fibrillation
3.2.2 Restraints
3.2.2.1 Stringent FDA, CE and European Medicines Agency product approval regulations
3.2.3 Opportunities
3.2.3.1 Introduction of innovative treatment procedures
3.2.3.2 Rising prevalence of atrial fibrillation in emerging Asian economies
3.3 Porter’s Five Forces Analysis for the Global Atrial Fibrillation Market
3.3.1 Bargaining Power of Suppliers
3.3.2 Bargaining Power of Buyers
3.3.3 Threat of Substitutes
3.3.4 Threat of New Entrants
3.3.5 Competitive Rivalry

Chapter 4 Atrial Fibrillation Market, by Treatment Types
4.1 Overview
4.1.1 Global Atrial Fibrillation Market, 2011 – 2019 (USD Million)
4.2 Global Pharmacological Treatments for Atrial Fibrillation Market
4.2.1 Global Pharmacological Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
4.2.2 Global Anti-Arrhythmic Drugs Market
4.2.2.1 Global Anti-Arrhythmic Drugs Market, 2011 – 2019 (USD Million)
4.2.3 Global Anti-Coagulants Market
4.2.3.1 Global Anti-Coagulant Drugs for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
4.3 Non-Pharmacological Treatment for Atrial Fibrillation Market
4.3.1 Overview: Comparative Analysis of the Non-Pharmacological Treatment for Atrial Fibrillation Market
4.3.2 Global Non-Pharmacological Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
4.3.3 Global Catheter Ablation Treatment for Atrial Fibrillation Market
4.3.3.1 Overview
4.3.3.2 Global Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
4.3.3.3 Global Radiofrequency Based Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
4.3.3.4 Global HIFU (High Intensity Focused Ultrasound) Based Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
4.3.3.5 Global Cryoablation Based Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
4.3.3.6 Global Microwave Based Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
4.3.3.7 Global Laser Based Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
4.3.4 Global Maze Surgery for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
4.3.5 Global Electric Cardioversion for Atrial Fibrillation Market, 2011 – 2019 (USD Million)

Chapter 5 Atrial Fibrillation Market, by Geography
5.1 Overview
5.2 North America
5.2.1 North America Atrial Fibrillation Market, by Treatment Types, 2011 – 2019 (USD Million)
5.3 Europe
5.3.1 Europe Atrial Fibrillation Market, by Treatment Types, 2011 – 2019 (USD Million)
5.4 Asia-Pacific
5.4.1 Asia-Pacific Atrial Fibrillation Market, by Treatment Types, 2011 – 2019 (USD Million)
5.5 Rest of the World (RoW)
5.5.1 RoW Atrial Fibrillation Market, by Treatment Types, 2011 – 2019 (USD Million)

Chapter 6 Competitive Landscape

Chapter 7 Recommendations
7.1 Investing in emerging markets, particularly China and Brazil
7.2 Focus on emerging technologies such as mini-maze procedure and catheter ablation

Chapter 8 Company Profiles
8.1 AtriCure, Inc.
8.1.1 Company Overview
8.1.2 Financial Overview
8.1.3 Product Portfolio
8.1.4 Business Strategies
8.2 Biosense Webster, Inc.
8.2.1 Company Overview
8.2.2 Product Portfolio
8.2.3 Business Strategies
8.3 Boehringer Ingelheim GmbH
8.3.1 Company Overview
8.3.2 Financial Overview
8.3.3 Product Portfolio
8.3.4 Business Strategies
8.3.5 Recent Developments
8.4 Boston Scientific Corporation
8.4.1 Company Overview
8.4.2 Financial Overview
8.4.3 Product Portfolio
8.4.4 Business Strategies
8.5 Bristol-Myers Squibb Corporation
8.5.1 Company Overview
8.5.2 Financial Overview
8.5.3 Product Portfolio
8.5.4 Business Strategies
8.6 CardioFocus, Inc.
8.6.1 Company Overview
8.6.2 Product Portfolio
8.7 Endoscopic Technologies, Inc.
8.7.1 Company Overview
8.7.2 Product Portfolio
8.7.3 Business Strategies
8.8 Sanofi Aventis
8.8.1 Company Overview
8.8.2 Financial Overview
8.8.3 Product Portfolio
8.8.4 Business Strategies
8.9 St. Jude Medical, Inc.
8.9.1 Company Overview
8.9.2 Financial Overview
8.9.3 Product Portfolio
8.9.4 Business Strategies
8.10 Johnson and Johnson Ltd
8.10.1 Company Overview
8.10.2 Financial Overview
8.10.3 Product Portfolio
8.10.4 Business Strategies

List of Figures

FIG. 1 Market Segmentation: Global Atrial Fibrillation Market
FIG. 2 Global Atrial Fibrillation Market, by Treatment Types, 2012 (USD Million)
FIG. 3 Global Population, by Age-Group, 2000 & 2050 (%)
FIG. 4 Porter’s Five Forces Analysis for the Global Atrial Fibrillation Market
FIG. 5 Comparative Analysis of the Global Atrial Fibrillation Market, by Treatment Types, 2012 & 2019 (%)
FIG. 6 Global Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 7 Global Pharmacological Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 8 Global Anti-Arrhythmic Drugs Market, 2011 – 2019 (USD Million)
FIG. 9 Global Anti-Coagulant Drugs for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 10 Comparative Analysis of the Non-Pharmacological Treatment for Atrial Fibrillation Market
FIG. 11 Global Non-Pharmacological Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 12 Comparative Analysis: Catheter Ablation Treatment Types for the Atrial Fibrillation Market
FIG. 13 Global Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 14 Global Radiofrequency Based Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 15 Global HIFU (High Intensity Focused Ultrasound) Based Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 16 Global Cryoablation Based Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 17 Global Microwave Based Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 18 Global Laser Based Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 19 Global Maze Surgery for Atrial Fibrillation Market, 2013 – 2019 (USD Million)
FIG. 20 Global Electric Cardioversion for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 21 Comparative Analysis of the Global Atrial Fibrillation Market, by Geography, 2012 & 2019 (%)
FIG. 22 North America Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 23 Europe Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 24 Asia-Pacific Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 25 RoW Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 26 AtriCure Inc.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 27 Boehringer Ingelheim: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 28 Boston Scientific: Annual sales revenue, 2010 – 2012 (USD Million)
FIG. 29 Bristol-Myers Squibb: Annual sales revenue, 2010 – 2012 (USD Million)
FIG. 30 Sanofi: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 31 St. Jude Medical: Annual Sales Revenue, 2010 – 2012 (USD Million)
FIG. 32 Johnson and Johnson: Annual Revenue, 2010 – 2012 (USD Million)

List of Tables

TABLE 1 Market Snapshot: Global Atrial Fibrillation Market
TABLE 2 Impact analysis of the Market Drivers for the Global Atrial Fibrillation Market
TABLE 3 Impact analysis of the Market Restraints for the Global Atrial Fibrillation Market
TABLE 4 Anti-Arrhythmic Drug Types and Clinical Usage
TABLE 5 Anti-Arrhythmic Drugs: Classification and Clinical Usage
TABLE 6 North America Atrial Fibrillation Market, by Treatment Types, 2011 – 2019 (USD Million)
TABLE 7 Europe Atrial Fibrillation Market, by Treatment Types, 2011 – 2019 (USD Million)
TABLE 8 Asia-Pacific Atrial Fibrillation Market, by Treatment Types, 2011 – 2019 (USD Million)
TABLE 9 RoW Atrial Fibrillation Market, by Treatment Types, 2011 – 2019 (USD Million)

FEATURED COMPANIES

  • AtriCure, Inc
  • Biosense Webster, Inc
  • Boehringer Ingelheim GmbH
  • CardioFocus, Inc
  • Johnson and Johnson Ltd
  • Sanofi Aventis
  • MORE

The atrial fibrillation market on the basis of geography is segmented into four regions namely North America, Asia-Pacific, Europe and rest of the world (RoW). The North American atrial fibrillation market held the majority of the market share in 2012 on account of the following factors:

- High prevalence of atrial fibrillation. According to the estimates of the U.S. CDC, the prevalence of atrial fibrillation was 2.66 million in 2010. Moreover, its prevalence is estimated to reach 12 million by 2050.

- The high atrial fibrillation prevalence coupled with the presence of high disposable incomes of patients, the presence of a robust reimbursement infrastructure and rising healthcare expenditure are some of the major factors driving the growth of North America atrial fibrillation market.

The North American region was followed by Europe in terms of market share in 2012. The Asia-Pacific atrial fibrillation market is expected to grow at the highest CAGR on account of the rising prevalence of atrial fibrillation in China coupled with the introduction of new healthcare reforms and rapid economic development in the country.

In terms of treatment types, the overall atrial fibrillation market is segmented into two type’s namely pharmacological and non-pharmacological treatment markets. The global atrial fibrillation treatment market was dominated by the pharmacological treatment procedures (involving anti-arrhythmic drugs, rate control drugs, chemical cardioversion and anti-coagulants) in terms of market share in 2012. This valuation is justified by the following reasons:

- Drugs are consumed more frequently by patients, sometimes simultaneously with non-pharmacological treatment procedures. For e.g. patients are advised to consume anti-coagulant drugs before an electric cardioversion and patients are administered with anti-coagulants post a catheter ablation procedure to reduce the risk of a stroke.

- Drugs are a cheaper alternative to expensive non-pharmacological procedures such as catheter ablation and surgeries. However, this fact is not applicable to all the patients as in most of the cases cardiologists recommend the most appropriate and therefore inevitable treatment procedures to patients suffering from atrial fibrillation.

The market share of pharmacological treatment procedures is expected to increase to over 55% in 2019 on account of the introduction of new and advanced drugs such as anti-coagulants dabigatran and rivaroxaban.

- AtriCure, Inc
- Biosense Webster, Inc
- Boehringer Ingelheim GmbH
- Boston Scientific Corporation
- Bristol-Myers Squibb Corporation
- CardioFocus, Inc
- Endoscopic Technologies, Inc
- Johnson and Johnson Ltd
- Sanofi Aventis
- St Jude Medical, Inc

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos